Quick Answer
Valion Bio, Inc. reported Net Income of -$8.88 million for fiscal year 2025.
Valion Bio, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$8.88M | -57.0% |
| 2024 | -$5.66M | +31.4% |
| 2023 | -$8.24M | +18.3% |
| 2022 | -$10.10M | -18.9% |
| 2021 | -$8.49M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.60M | -81.4% | -34.4% |
| June 30, 2025 | -$1.93M | -52.5% | -28.6% |
| March 31, 2025 | -$1.50M | -1.4% | -5.0% |
| September 30, 2024 | -$1.43M | +18.7% | -13.0% |
| June 30, 2024 | -$1.27M | +40.4% | +14.5% |
| March 31, 2024 | -$1.48M | +30.0% | +15.9% |
| September 30, 2023 | -$1.76M | +31.9% | +17.2% |
| June 30, 2023 | -$2.12M | +29.6% | -0.4% |
- Valion Bio, Inc. showed a decrease of -57.0% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Valion Bio, Inc.’s net income has declined by 4.5% (from -$8.49 million to -$8.88 million).
- The most recent figure is from Valion Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: